Clinical Trial Update: Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tolerability, safety, and efficacy of inhaled AZD4818 in adults with moderate to severe COPD. Results were posted in 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• AZD4818

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Status: COMPLETED | Results posted: 2010-12-06